Bioactivity of Farnesyltransferase Inhibitors Against *Entamoeba histolytica* and *Schistosoma mansoni*

Alexandra Probst 1, Thi N. Nguyen 1, Nelly El-Sakkary 1, Danielle Skinner 1, Brian M. Suzuki 1, Frederick S. Buckner 2, Michael H. Gelb 3, Conor R. Caffrey 1* and Anjan Debnath 1*

1 Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, United States; 2 Division of Allergy and Infectious Diseases, Department of Medicine, Center for Emerging and Reemerging Infectious Diseases, University of Washington, Seattle, WA, United States; 3 Departments of Chemistry and Biochemistry, University of Washington, Seattle, WA, United States

The protozoan parasite *Entamoeba histolytica* can induce amebic colitis and amebic liver abscess. First-line drugs for the treatment of amebiasis are nitroimidazoles, particularly metronidazole. Metronidazole has side effects and potential drug resistance is a concern. Schistosomiasis, a chronic and painful infection, is caused by various species of the *Schistosoma* flatworm. There is only one partially effective drug, praziquantel, a worrisome situation should drug resistance emerge. As many essential metabolic pathways and enzymes are shared between eukaryotic organisms, it is possible to conceive of small molecule interventions that target more than one organism or target, particularly when chemical matter is already available. Farnesyltransferase (FT), the last common enzyme for products derived from the mevalonate pathway, is vital for diverse functions, including cell differentiation and growth. Both *E. histolytica* and *Schistosoma mansoni* genomes encode FT genes. In this study, we phenotypically screened *E. histolytica* and *S. mansoni in vitro* with the established FT inhibitors, lonafarnib and tipifarnib, and with 125 tipifarnib analogs previously screened against both the whole organism and/or the FT of *Trypanosoma brucei* and *Trypanosoma cruzi*. For *E. histolytica*, we also explored whether synergy arises by combining lonafarnib and metronidazole or lonafarnib with statins that modulate protein prenylation. We demonstrate the anti-amebic and anti-schistosomal activities of lonafarnib and tipifarnib, and identify 17 tipifarnib analogs with more than 75% growth inhibition at 50 µM against *E. histolytica*. Apart from five analogs of tipifarnib exhibiting activity against both *E. histolytica* and *S. mansoni*, 10 additional analogs demonstrated anti-schistosomal activity (severe degenerative changes at 10 µM after 24 h). Analysis of the structure-activity relationship available for the *T. brucei* FT suggests that FT may not be the relevant target in *E. histolytica* and *S. mansoni*. For *E. histolytica*, combination of metronidazole and lonafarnib resulted in synergism for growth inhibition. Also, of a number of statins tested, simvastatin exhibited moderate anti-amebic activity which, when combined with lonafarnib, resulted in slight synergism. Even in the absence of a definitive molecular target, identification of potent anti-parasitic tipifarnib analogs encourages further exploration while the synergistic combination of metronidazole and lonafarnib offers a promising treatment strategy for amebiasis.

Keywords: *Entamoeba histolytica*, *Schistosoma mansoni*, farnesyltransferase, metronidazole, lonafarnib, tipifarnib, statin, chemotherapy
INTRODUCTION

*Entamoeba histolytica* is a non-flagellated protozoan parasite exclusive to humans that has a simple life cycle comprising an infective cyst stage and an invasive trophozoite form (Petri and Singh, 1999; Stanley, 2003). Infection with *E. histolytica* can lead to three major outcomes: (a) asymptomatic colonization, (b) intestinal amebiasis, most commonly amebic colitis, and (c) extra-intestinal amebiasis with liver abscess being the most common complication (Petri and Singh, 1999). Amebiasis causes up to 110 thousand deaths annually and is estimated to be the second most common cause of parasite infection-related mortality worldwide (Petri and Singh, 1999; Lozano et al., 2012; Watanabe and Petri, 2015). Each year 40 to 50 million cases of amebic colitis and liver abscess are reported with high prevalences in Central and South America, Africa, and Asia (Petri and Singh, 1999).

Amebic infection is initiated by ingestion of *E. histolytica* cysts in fecally contaminated food or water. These cysts excyst in the intestine to form trophozoites, which degrade the mucous layer via cysteine protease activities, destroy and ingest epithelial cells via trypocytosis, and invade the lamina propria, which leads to colitis and liver abscesses in the case of invasion of the blood vessels (Petri, 2002; Stauffer and Ravdin, 2003; Watanabe and Petri, 2015).

First-line drugs for the treatment of invasive amebiasis are the nitroimidazoles, in particular metronidazole, which is given orally to adults in three doses of 750 mg (total 2,250 mg/day) per day for 7–10 days (Haque et al., 2003). Nitroimidazole compounds carry a nitro group on the 5-position of the imidazole ring. As prodrugs, that must be activated by reductases of the parasite. After entering the trophozoite, reduced feredoxin donates electrons to the nitro group of the prodrug, which is then reduced to toxic radicals. Covalent binding to DNA macromolecules results in DNA damage and killing of the parasites (Muller, 1983; Edwards, 1993). Nitroreductases and thioredoxin reductase are also known to reduce nitroimidazole drugs in *Entamoeba* (Leitsch et al., 2007).

Potential resistance of *E. histolytica* to metronidazole remains a major concern (Samarawickrema et al., 1997; Wassmann et al., 1999) and in the absence of a back-up drug, it is important to search for alternative antimicrobials against *E. histolytica*.

Schistosomiasis is caused by various species of the *Schistosoma* flatworm that reside in the venous system. Infection is found in populations living close to freshwater bodies that harbor the appropriate vector snail. With as many as 200 million people infected (Hotez, 2018) and possibly over 700 million at risk (King, 2010), infections can be chronic and painful as a consequence of progressive tissue and organ damage due to the parasite’s eggs. The disease impacts school attendance and performance, the ability to work, and, consequently, it has been considered a direct contributor to poverty (Hotez et al., 2008; Utzinger et al., 2011). Treatment and control of schistosomiasis relies on just one drug, praziquantel. Though safe and reasonably effective, the drug is rarely curative and is less effective against immature parasites (Caffrey, 2007, 2015). The possibility of resistance, particularly as dissemination of the drug is increasing (http://unitingtocolombatntds.org/wp-content/themes/tetloose/app/staticPages/fifthReport/files/fifth_progress_report_english.pdf, 2014) is a constant concern, and alternative drugs would be welcome.

The mevalonate metabolic pathway is vital for diverse functions in parasitic protozoa and helminths such as sterol synthesis and cell growth (Li et al., 2013; Rojo-Arreola et al., 2014; Millerioux et al., 2018). 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGR) is the rate-limiting enzyme in the pathway which catalyzes the conversion of HMG-CoA into mevalonate (Edwards and Ericsson, 1999). HMGR inhibitors, also known as statins, prevent the conversion of HMG-CoA to L-mevalonate resulting in the inhibition of the downstream sterol biosynthesis (Gazzero et al., 2012). Mevalonate is also a precursor of isoprenoid groups, in addition to more than a dozen classes of end products (Goldstein and Brown, 1990). The last common substrate for the synthesis of the end products of the mevalonate pathway is farnesyl pyrophosphate (FPP, also referred to as farnesyl diphosphate FDP). It is the natural substrate of farnesyl transferase (FT), which catalyzes the transfer of a farnesyl moiety from FPP to proteins. Farnesylated proteins include Ras and Ras related GTP-binding proteins, nuclear lamins, centromere-associated proteins, tyrosine phosphatases, and co-chaperones (Zhang and Casey, 1996). FT catalyzes the prenylation of proteins through a thioether linkage and the prenylation may be concluded by the palmitoylation of cysteine residues for some proteins. Due to the lipids involved in the mechanism and their hydrophobicity, prenylation leads to membrane interactions by the proteins and plays an important role in the signal transduction pathway for cell differentiation (Zhang and Casey, 1996). A previous characterization of *E. histolytica* FT showed that the amebic FT did not utilize a majority of Ras and Rap as substrates, but only one Ras protein, Ras4, was farnesylated (Kumagai et al., 2004). *Schistosoma mansoni* Ras was also found to be farnesylated and inhibition of farnesylation in *S. mansoni* extract was achieved using an FT inhibitor (FTI) (Osman et al., 1999). The deduced amino acid sequences of the β-subunit of both *E. histolytica* and *S. mansoni* FT were 36 and 43% identical to the β-subunit of human FT. There is evidence that targeting the farnesyltransferase enzyme in protozoan parasites leads to inhibition of protein prenylation and severely impairing growth, including *Plasmodium falciparum* (Ibrahim et al., 2001; Buckner et al., 2002; Chakrabarti et al., 2002; Carrico et al., 2004; Esteva et al., 2005). Here, we demonstrate the anti-parasitic activities of known FTIs lonafarnib and tipifarnib against *E. histolytica*, and *S. mansoni* somules (post-infective larvae) and adults. In addition, we identified tipifarnib analogs with anti-amebic and anti-schistosomal activities. The combination of lonafarnib with the currently used anti-amebic drug, metronidazole, generated a synergistic growth inhibition of *E. histolytica*.

MATERIALS AND METHODS

Chemicals and Reagents

Assay plates (format includes: 96- and 24-well; flat and U-bottomed; and transparent and white) were purchased from VWR International (Radnor, PA). The CellTiter-Glo luminescent
cell viability assay was acquired from Promega (Madison, WI); DMSO, metronidazole, lonafarnib and simvastatin were purchased from Sigma-Aldrich (St. Louis, MO). The tipifarnib analogs (Figure 1) were previously synthesized as part of a program to develop FTIs active against Trypanosoma brucei and Trypanosoma cruzi, the causative agents of Human African Trypanosomiasis and Chagas disease, respectively (Kraus et al., 2009, 2010). Compounds were dissolved in DMSO at a concentration of 10 mM and stored at −20°C.

Maintenance of Entamoeba histolytica
E. histolytica trophozoites (strain HM1:IMSS) were maintained axenically in TYI-S-33, supplemented with penicillin (100 U/mL), streptomycin (100 µg/mL) and 10% heat inactivated adult bovine serum as previously described (Diamond et al., 1978). The cells were maintained in the logarithmic phase of growth by routine passage every 2 days and the logarithmic phase of growth was determined by counting the cells using a hemocytometer.

Maintenance of Schistosoma mansoni
The NMRI isolate of S. mansoni was maintained by passage through Biomphalaria glabrata snails and 3–5 week-old, female Golden Syrian hamsters (Charles River, San Diego, CA) as intermediate and definite hosts, respectively (Abdulla et al., 2009; Long et al., 2016). A dose of 600 infective larvae (cercariae) was used to infect hamsters. The acquisition, preparation and in vitro maintenance of S. mansoni post-infective larvae (schistosomula or somules) and adults have been described (Abdulla et al., 2009; Štefanić et al., 2010). Vertebrate maintenance and handling at the University of California San Diego Animal Care Facility were in accordance with protocols approved by the university’s Institutional Animal Care and Use Committee (IACUC).

First-Pass Screening of the FTIs and Statins for Activity Against Entamoeba histolytica
A first-pass cell viability assay was performed with compounds at a concentration of 50 µM against E. histolytica (Debnath et al., 2014). Briefly, 0.5 µL of 10 mM (FTIs) or 20 mM (statins) stock compounds were plated into white 96-well flat-bottom plates in duplicate and 5,000 trophozoites in 99.5 µL TYI-S-33 medium were added to the 96-well plates. As a positive control, 50 µM of metronidazole were plated; negative controls contained 0.5% of DMSO. Cell culture plates were incubated at 37°C for 48 h in the GasPak EZ gas-generating anaerobe pouch system (VWR). After incubation, 50 µL of CellTiter-Glo® were added. The luminescent signal, resulting from the lysis of the cells was measured by an EnVision luminometer, and can be converted into the percentage of inhibition of the cell growth relative to maximum and minimum reference signal controls by using the following equation (Debnath et al., 2012):

\[
\%\ Inh. = \left( 1 - \frac{\text{luminescent output (RLU) of compound x} - \text{mean of luminescent output (RLU) of positive control}}{\text{mean of luminescent output (RLU) of negative control} - \text{mean of luminescent output (RLU) of positive control}} \right) \times 100
\]

Dose-Response Assays of the FTIs Lonafarnib and Tipifarnib, Simvastatin as Well as Metronidazole Against Entamoeba histolytica
Dose-response assays were implemented as confirmatory screens of FTIs, simvastatin and metronidazole against E. histolytica trophozoites. An 8-point EC50 determination (half maximal effective concentration) was performed as follows: 0.5 µL of 10 mM (FTIs) or 20 mM (simvastatin) stock compounds was plated in triplicate into white 96-well flat-bottom plates to obtain a starting concentration range of 50 to 0.39 µM for FTIs and 100 to 0.78 µM for simvastatin. The addition of the cells, the incubation and the reading were performed as described in the first-pass assay. Graph, EC50 calculations and standard error (fitting method: least square (ordinary) fit) were obtained by using GraphPad Prism (San Diego, CA) (Debnath et al., 2012).

Mammalian Cytotoxicity Assay
Tipifarnib was screened for cytotoxicity against the fibroblast 3T3 cell line. Cells were grown in the presence of tipifarnib for 48 h before growth was quantified using Alamar Blue (Alamar Biosciences Inc., Sacramento, CA) (Kraus et al., 2009). Tipifarnib was tested at final concentrations of 100, 50, 25, 12.5, 6.25, 3.13, 1.56, and 0.78 µM.

Entamoeba histolytica Invasion Assay
This was performed as described previously (Emmanuel et al., 2015). Briefly, 75,000 E. histolytica trophozoites were pre-incubated for 3 h with 0.5% DMSO, 14 and 25 µM of tipifarnib and after 3 h, cells were re-suspended in serum-free TY1 medium and loaded in the upper chamber of a Corning BioCoat Matrigel Invasion Chamber (Corning). The lower chamber contained TY1 medium supplemented with 10% adult bovine serum (Sigma-Aldrich). The Matrigel Invasion Chamber was incubated at 37°C for 48 h in a GasPak EZ gas-generating anaerobe pouch system. At the end of incubation, images of trophozoites in the lower chamber were captured using a 10 × objective lens fitted in a Zeiss Axiosvert A1 inverted microscope. Trophozoites that had migrated into the lower chamber were also counted using a hemocytometer. The data were obtained from three independent experiments each performed in triplicate and the percentage invasion of trophozoites was calculated and plotted by using GraphPad Prism.

Combination Assays
Because the activity of tested FTIs and simvastatin against E. histolytica was moderate when administered alone, we tested if a combination of lonafarnib with metronidazole or an HMG-CoA reductase inhibitor (simvastatin) would have a better activity against E. histolytica in vitro than a single compound. Drugs were combined at constant ratios 1:1, 1:2, 1:4, 1:8,
2:1, 4:1, 8:1, 16:1 [µM lonafarnib/µM metronidazole and µM lonafarnib/µM simvastatin]. Growth inhibition was determined with the CellTiter-Glo® luminescent cell viability assay, as described previously (Debnath et al., 2012). Quantitative drug interaction (synergy) was determined by using the software CompuSyn (Chou and Talalay, 1984; Chou, 2006).

Phenotypic Evaluation of the Effect of Combination of Lonafarnib and Metronidazole on Entamoeba histolytica Trophozoites

The assay was performed using transparent 96-well flat-bottom plates. DMSO was used as a negative control at a final concentration of 0.5%. Metronidazole was plated at 50 µM as a positive control. Lonafarnib and metronidazole were combined at ratios of 4:1, 2:1, 1:1, 1:2, and 1:4. Parasites were plated and incubated for 48 h as described in the first pass and dose response assay for E. histolytica (Debnath et al., 2014). Images were captured after 24 and 48 h post-incubation using a Zeiss Axiovert A1 inverted microscope (10×, 20×, 40× and 63× objective) and a Zeiss AxioCam 503 mono digital camera controlled by the Zen 2 lite software (Version 2.0.0.0).

Phenotypic Screening of FTIs With Different Developmental Stages of Schistosoma mansoni

Screens were performed using post-infective larvae (somules) and adult parasites, as described (Abdulla et al., 2009; Rojo-Arreola et al., 2014; Long et al., 2016) using transparent U-shaped 96-well plates and flat-bottom 24-well plates, respectively. Given the relatively large number of compounds to screen, the entire collection was screened against somules to identify the most active compounds for subsequent screening against adult parasites, as conducted previously (Abdulla et al., 2009). Somules are harvestable in their thousands from vectors snails whereas adults are only recoverable from infected hamsters in limited numbers (~10–20% return on the infecting 600 cercarial dose used).

Somules (40 units/well) were prepared in 100 µL Basch medium (Basch, 1981) supplemented with 5% FBS, 100 U/mL penicillin and 100 µg/mL streptomycin. Compounds were then added at 2x the final concentration in 100 µL of the same medium to yield final concentrations of 5 or 10 µM compound and 0.5% DMSO. Parasites were incubated at 37°C in a 5% CO2 environment and phenotypic changes recorded at 24 and 48 h. Adult 42-day-old S. mansoni (5 males and including approximately 2 pairs) was maintained in 2 ml of the same Basch medium under the same conditions in the presence of 10 µM compound and 0.1% DMSO. Phenotypic changes were recorded at 1, 5, 24, and 48 h.

Phenotypic changes are recorded as described (Abdulla et al., 2009; Rojo-Arreola et al., 2014; Glaser et al., 2015; Weeks et al., 2018). Briefly, we employ simple descriptors that describe the effects of compounds on the parasites (changes in shape, motility, and density). To allow for comparisons of compound activity, each descriptor is awarded a “severity score” of 1 and these are added up to a maximum score of 4. Evidence of degeneracy or death is awarded the maximum score of 4, and, for adults specifically, non-adherence by the oral or ventral suckers to the well surface (a score of 1) is taken into account as is damage to the outer surface (tegument; a score of 4) on the understanding that such damage is lethal in vivo to the parasite (Andrews et al., 1983). Images were captured via a Zeiss AxioCam 105 color digital camera that was attached to a Zeiss Axiovert A1 inverted microscope and controlled by ZEN 2 lite software (Version 2.0.0.0).

RESULTS

First-Pass Screening of FTIs (Lonafarnib, Tipifarnib, 125 Analogs of Tipifarnib) and Statins Against Entamoeba histolytica

Table 1 lists the most active statins and FTIs that were obtained from the first pass screening against E. histolytica trophozoites (>75% growth inhibition). From the five statins tested (mevastatin, atorvastatin, fluvastatin, pitavastatin, simvastatin), only simvastatin exhibited 94% growth inhibition at 100 µM. Lonafarnib, tipifarnib and 17 tipifarnib analogs (Table 1) demonstrated >75% of inhibition at 50 µM after an incubation period of 48 h. Both lonafarnib and tipifarnib demonstrated...
almost 100% inhibitory activity and one tipifarnib analog, HB-24 showed 98.9% inhibition at 50 μM. The results of the first-pass screening against *E. histolytica* trophozoites for all 125 tipifarnib analogs are shown in Supplementary Table 1. Activities were stratified into four groups depending on the percentage growth inhibition of *E. histolytica* trophozoites. Compounds showing 75–100% growth inhibition belonged to group A, group B showed 50–74% inhibition, group C had 25–49% growth inhibition and group D exhibited 0–24% growth inhibition. In referencing to the generic structure shown in Figure 1 (right), most of the active compounds contain R3 = NH2 (11 of 17). For the analogs, ring 1 was either left the same as tipifarnib (4-Cl) or modified to 4-CH3, 4-CF3, 3-Cl, or several other variants. There were no apparent trends associating specific ring 1 substituents with more potent *E. histolytica* activity. With respect to ring 2, compounds with the 3-Cl-phenyl (as occurs with tipifarnib) were found in groups 1, 2, 3, and 4.

**Entamoeba histolytica Concentration Response Assay**

As simvastatin and FTIs tipifarnib and lonafarnib were among the most active compounds in the primary screen, they were selected for further testing. Some of the active tipifarnib analogs containing NH2 at R3 were also assessed for EC50. The EC50 of simvastatin was 50 μM, whereas both tipifarnib and lonafarnib generated EC50 values of about 14 μM. The EC50 value for tipifarnib on a mammalian fibroblast cell line 3T3 was 94 μM. This provided a selectivity index of about 2.5. The most active tipifarnib analog in the primary screen, HB-24, generated an EC50 value similar to those of lonafarnib or tipifarnib (Table 2). The dose response and EC50 data for simvastatin, tipifarnib, lonafarnib, and metronidazole are displayed in Figure 2 and Table 2, respectively.

### Table 1 | Activity of statins at 100 μM and tipifarnib analogs at 50 μM against *E. histolytica*.

| Compound name | Growth inhibition (%) |
|---------------|-----------------------|
| Simvastatin   | 94                    |
| Tipifarnib    | 99                    |
| Lonafarnib    | 100                   |
| CHN-12        | 77.1                  |
| CHN-13        | 86.6                  |
| CHN-14        | 77.1                  |
| HB-15         | 78.6                  |
| HB-21         | 90.2                  |
| HB-24         | 98.9                  |
| HB-27         | 95.5                  |
| HB-30         | 86.3                  |
| JK-02         | 75.1                  |
| JK-12         | 91.5                  |
| JK-13         | 83.2                  |
| JK-17         | 92.6                  |
| JK-19         | 81.9                  |
| JK-21         | 77.0                  |
| JK-31         | 84.0                  |
| PN-103        | 77.0                  |
| PN-133        | 78.0                  |

### Table 2 | EC50 values of simvastatin, FTIs, tipifarnib analogs, and metronidazole against *E. histolytica*.

| Compound name | EC50 ± SE (μM)3 |
|---------------|-----------------|
| Simvastatin   | 50.2 ± 0.05     |
| Tipifarnib    | 14.2 ± 0.02     |
| Lonafarnib    | 14.5 ± 0.05     |
| CHN-13        | 27.6 ± 0.03     |
| HB-21         | 26.4 ± 0.03     |
| HB-24         | 17.5 ± 0.03     |
| JK-17         | 20.2 ± 0.03     |
| JK-31         | 26.2 ± 0.01     |
| Metronidazole | 3.7 ± 0.01      |

3EC50 minimum n = 3.

**Figure 2** | Concentration-dependent inhibition of growth of *E. histolytica* by tipifarnib, lonafarnib, and simvastatin, as compared to metronidazole. Different concentrations of compounds were tested in triplicate for activity against *E. histolytica* trophozoites. The data points represent mean percentage growth inhibition and standard error of mean (SEM) of different concentrations of metronidazole, tipifarnib, lonafarnib and simvastatin. EC50 curves were generated from mean values of percentage growth inhibition ± SEM of metronidazole, tipifarnib, lonafarnib, and simvastatin against *E. histolytica*.

**Entamoeba histolytica Invasion Assay**

To test whether tipifarnib influences invasiveness of *E. histolytica*, we used a transwell matrigel invasion assay. The data show that a 3 h pre-incubation of trophozoites with tipifarnib at its EC50 concentration (14 μM) or at 25 μM decreased the invasion of trophozoites through the matrigel after 48 h compared to 0.5% DMSO-treated trophozoites (Figure 3). Specifically, whereas 68.7 ± 5.7% of the DMSO-treated trophozoites penetrated the matrigel and were recovered in the lower chamber, just 23.2 ± 5.7% (p = 0.005) and 7.3 ± 2.3% of the cells (p = 0.0005) that had been exposed to 14 and 25 μM tipifarnib were recovered, respectively.

**Synergy Assay of Lonafarnib and Metronidazole Against *Entamoeba histolytica***

To measure the effect of combining lonafarnib and metronidazole, drugs were combined at constant micromolar ratios and the inhibition of *E. histolytica* trophozoites growth was
Probst et al. Farnesyltransferase Inhibitors Against Entamoeba, Schistosoma

FIGURE 3 | Effect of tipifarnib on invasion of matrigel by *E. histolytica*. *E. histolytica* trophozoites were incubated for 3 h with 0.5% DMSO, 14 µM of tipifarnib and 25 µM of tipifarnib and at the end of incubation trophozoites were allowed to invade the matrigel for 48 h. After 48 h, the migrated cells in the lower chamber were counted and percentage invasion of trophozoites was calculated and plotted (A). Images of trophozoites at 48 h were captured using a Zeiss Axiovert A1 inverted microscope and a Zeiss AxioCam 503 mono digital camera controlled by Zen 2 lite software. Trophozoites were treated for 3 h with 0.5% DMSO (B), 14 µM tipifarnib (C), and 25 µM tipifarnib (D) and migrated trophozoites in lower chambers were imaged at 48 h. Trophozoites were photographed at 10 × magnification. Arrow indicates *E. histolytica* trophozoites. **P < 0.01 and ***P < 0.001 by Student’s t-test compared to 0.5% DMSO-treated *E. histolytica* trophozoites.

determined using the CellTiter-Glo® luminescent cell viability assay. Synergism was observed for all combinations of lonafarnib and metronidazole at 50, 75, 90, and 95% of growth inhibition, respectively. Synergism at high effect level is much more relevant than at low effect level, therefore a 95% growth inhibition of *E. histolytica* trophozoites upon drug administration was chosen to be presented in Table 3. All tested combinations of lonafarnib and metronidazole showed synergism, given the combination index (CI) values being <1. According to Chou (Chou, 2006), CI values ranging from 0.85 to 0.9 indicate slight synergism,
values in the range of 0.7 to 0.85 and 0.3 to 0.7 indicate moderate synergism and synergism, respectively. Combining lonafarnib and metronidazole led to a reduction of each dose (Dose Reduction Index or DRI) at given effect level compared with the doses of each drug alone.

### Phenotypic Screening of FTIs Against Schistosoma mansoni

Because the anti-schistosomal activity of statins, including mevastatin, atorvastatin, fluvastatin and simvastatin, has already been demonstrated against *S. mansoni* somules and adults (Rojo-Arreola et al., 2014; Asarnow et al., 2015), the phenotypic screening in this study focused on the FTIs.

For somules, phenotypic changes in the presence of the FTIs were assessed visually after 24 and 48 h at 5 and 10 µM (Figure 5 as a representative example), and the descriptors recorded were converted to severity scores to allow for comparison of compound activities. Based on the combination of time- and dose-dependency of activity, the compounds could be ranked into four groups (Groups A-D; Supplementary Table 2). Group A comprised the 17 most active compounds that generated severity scores of 3 or 4 at either 5 or 10 µM after 48 h (Table 7). These included lonafarnib and tipifarnib. Group B comprised 47 compounds that were maximally active (score of 4) at both 24 and 48 h at 10 µM, but elicited little or no activity at 5 µM. The 34 Group C compounds were those for which severity scores of 1–3 were recorded at 10 µM after 24 h and, finally, the 28 Group D compounds were those that registered zero scores at 10 µM after 24 h. Throughout, the most common phenotypic responses recorded were loss of translucency (darkening) and degeneracy sometimes leading to death.

The most active 17 Group A compounds were subsequently screened at 10 µM against 42-day-old adult *S. mansoni* and phenotypes recorded at 1, 5, 24, and 48 h. All were active to varying degrees (Table 7, Supplementary Table 2, Supplementary Videos 1, 2). Thus, the most common phenotypic responses of the parasites noted at 1 and 5 h was an uncoordinated motion coupled with an inability of the parasite to adhere via its oral or ventral suckers to the floor of the well (severity score of 2). By 24 and 48 h, for the 12 most active compounds, these responses had progressed to degeneracy, worm

## Phenotypic Screening of FTIs Against Schistosoma mansoni

Because the anti-schistosomal activity of statins, including mevastatin, atorvastatin, fluvastatin and simvastatin, has already been demonstrated against *S. mansoni* somules and adults (Rojo-Arreola et al., 2014; Asarnow et al., 2015), the phenotypic screening in this study focused on the FTIs.

For somules, phenotypic changes in the presence of the FTIs were assessed visually after 24 and 48 h at 5 and 10 µM (Figure 5 as a representative example), and the descriptors recorded were converted to severity scores to allow for comparison of compound activities. Based on the combination of time- and dose-dependency of activity, the compounds could be ranked into four groups (Groups A-D; Supplementary Table 2). Group A comprised the 17 most active compounds that generated severity scores of 3 or 4 at either 5 or 10 µM after 48 h (Table 7). These included lonafarnib and tipifarnib. Group B comprised 47 compounds that were maximally active (score of 4) at both 24 and 48 h at 10 µM, but elicited little or no activity at 5 µM. The 34 Group C compounds were those for which severity scores of 1–3 were recorded at 10 µM after 24 h and, finally, the 28 Group D compounds were those that registered zero scores at 10 µM after 24 h. Throughout, the most common phenotypic responses recorded were loss of translucency (darkening) and degeneracy sometimes leading to death.

The most active 17 Group A compounds were subsequently screened at 10 µM against 42-day-old adult *S. mansoni* and phenotypes recorded at 1, 5, 24, and 48 h. All were active to varying degrees (Table 7, Supplementary Table 2, Supplementary Videos 1, 2). Thus, the most common phenotypic responses of the parasites noted at 1 and 5 h was an uncoordinated motion coupled with an inability of the parasite to adhere via its oral or ventral suckers to the floor of the well (severity score of 2). By 24 and 48 h, for the 12 most active compounds, these responses had progressed to degeneracy, worm

### Table 3 | Summary of synergism assay with lonafarnib and metronidazole, shown for 95% growth inhibition of *E. histolytica* trophozoites.

| Drug combination ratio | % growth inhibition | CI | DRI | Dose required (µM) |
|------------------------|---------------------|----|-----|-------------------|
|                        |                     |    |     | Lonafarnib | Metronidazole | Lonafarnib | Metronidazole |
| Lonafarnib: metronidazole | Lonafarnib | Metronidazole | Lonafarnib | Metronidazole |
| 1:1                    | 95                   | 0.8 ± 0.04 | 10.1 ± 0.91 | 1.4 ± 0.03 | 9.4 ± 0.79 | 9.4 ± 0.79 |
| 1:2                    | 95                   | 0.7 ± 0.02 | 21.1 ± 2.6 | 1.4 ± 0.02 | 4.6 ± 0.29 | 9.1 ± 0.57 |
| 1:4                    | 95                   | 0.6 ± 0.12 | 53.8 ± 0.94 | 1.7 ± 0.37 | 1.9 ± 0.27 | 7.6 ± 1.08 |
| 1:8                    | 95                   | 0.6 ± 0.04 | 97.5 ± 17.17 | 1.6 ± 0.1 | 0.7 ± 0.49 | 5.6 ± 3.91 |
| 2:1                    | 95                   | 0.8 ± 0.05 | 8.2 ± 4.71 | 1.5 ± 0.05 | 17.6 ± 1.23 | 8.8 ± 0.62 |
| 4:1                    | 95                   | 0.7 ± 0.13 | 5.7 ± 3.62 | 2 ± 0.1 | 25.9 ± 0.65 | 6.5 ± 0.17 |
| 8:1                    | 95                   | 0.5 ± 0.14 | 5 ± 3.08 | 3.5 ± 0.23 | 29.7 ± 0.02 | 3.71 ± 0.01 |
| 16:1                   | 95                   | 0.6 ± 0.29 | 3.5 ± 2.43 | 4.8 ± 1.01 | 44.7 ± 7.5 | 2.8 ± 0.47 |
|                        | 95                   | 0.2 ± 0.29 | 0.49 ± 5.6 | 1.08 ± 0.17 | 85.4 ± 19.7 | 13 ± 0.9 |

The most active 17 Group A compounds were subsequently screened at 10 µM against 42-day-old adult *S. mansoni* and phenotypes recorded at 1, 5, 24, and 48 h. All were active to varying degrees (Table 7, Supplementary Table 2, Supplementary Videos 1, 2). Thus, the most common phenotypic responses of the parasites noted at 1 and 5 h was an uncoordinated motion coupled with an inability of the parasite to adhere via its oral or ventral suckers to the floor of the well (severity score of 2). By 24 and 48 h, for the 12 most active compounds, these responses had progressed to degeneracy, worm
shrinkage, decreased motility and blebbing of the surface tegument (severity scores of 3 or 4). Among the Group A compounds, and apart from lonafarnib and tipifarnib, only CHN-13, JK-02, JK-17, and JK-19 overlapped with those compounds that were most active against *E. histolytica* (Table 1).

Analysis of the physicochemical properties of all 125 compounds indicated that there was a statistically significant trend for compounds with higher cLogP values being associated with better *E. histolytica* and *S. mansoni* activity (Tables 5, 6).

**DISCUSSION**

We report the anti-parasitic activities of FTIs against two phylogenetically distinct parasites, the protozoan, *E. histolytica*, and the metazoan flatworm, *S. mansoni*. FT has gained much attention as a target for pharmaceutical development and a number of FTIs have been tested as anti-cancer agents (Bagchi et al., 2018). Both lonafarnib and tipifarnib are potent inhibitors of mammalian FT and have been extensively tested in clinical trials for malignancies (Martinelli et al., 2008; Moorthy et al., 2009).
Lonafarnib has also undergone clinical trials in children with progeria (Gordon et al., 2016). Thus, in an observational cohort study in patients with progeria, lonafarnib treatment led to a significantly reduced mortality rate after 2.2 years of follow-up (Gordon et al., 2018).

The role of protein farnesylation has been previously documented in *E. histolytica* (Kumagai et al., 2004). Specifically, the *E. histolytica* Ras4 (a small GTPase mediating cell proliferation/differentiation) was identified as a unique farnesyl acceptor for the *E. histolytica* FT (Kumagai et al., 2004). Molecular characterization of protein farnesyltransferase in *E. histolytica* demonstrated that α and β subunits are well-conserved signature domains shared by other organisms (Kumagai et al., 2004).

The studies reported herein demonstrate that two FTIs, lonafarnib and tipifarnib, were active against *E. histolytica* in culture with EC50 values of ∼14 µM. Because the compounds are less potent than the current standard metronidazole therapy, we screened a library of 125 tipifarnib analogs against *E. histolytica* in culture to identify compounds with greater potency and a structure-activity relationship (SAR). This library was originally assembled to target the protozoan parasite, Trypanosoma cruzi, and comprised compounds with known FTI activity as well as compounds with structural changes that abrogated that activity (Kraus et al., 2009, 2010). The changes were intended to reduce activity on the mammalian FT in order to avoid potential side-effects, while retaining anti-parasitic activity that was mediated through inhibition of the *T. cruzi* CYP51 enzyme (essential for ergosterol metabolism) (Kraus et al., 2009). The methylimidazole attached to the central sp3 carbon (Figure 1) is integral to the activity against both FT and sterol 14-alpha-demethylase (CYP51), and is retained in all of the analogs. However, changes to other substituents at positions R1–R3 (Figure 1, right) resulted in decreased FTI activity compared to tipifarnib (mammalian FT IC50 value of 0.7 nM). Specifically, introduction of a 2-methyl group on Ring 2 or replacing the tipifarnib Ring 2 with a naphthyl group yielded an IC50 value of 294 or 485 nM, respectively, against mammalian FT (Kraus et al., 2009). Combining the Ring 2 changes with a change of the NH2 to OMe at the R3 position essentially abrogated FTI activity (mammalian FT IC50 of >5,000 nM).

Previously reported whole-organism studies in vitro with tipifarnib demonstrated moderate bioactivity (EC50 = 6 µM) against the protozoan parasite, Trypanosoma brucei (Buckner et al., 2005), but much more potent activity against Trypanosoma cruzi (EC50 = 0.004 µM) (Kraus et al., 2010). Against the Trypanosoma brucei FT recombiantly expressed in *E. coli* (Buckner et al., 2000), tipifarnib analogs with R3 = NH2 (e.g., JK-02, JK-12, JK-13, JK-17, and JK-19), i.e., those that were active against *E. histolytica*, possess weak to negligible activity (data not published). Further, we previously demonstrated that 11 of the 17 most active tipifarnib analogs against *E. histolytica* and which contained the same NH2 R3 group (Supplementary Table 1) exert their activity against *T. cruzi* via inhibition of CYP51 (Kraus et al., 2009), yet, a CYP51 ortholog is not found in the *E. histolytica* genome (searching E.C. #1.14.13.70). Overall, therefore, it seems that the activity against *E. histolytica* is

### TABLE 4 | Summary of combination assay with lonafarnib and simvastatin, shown for 95% growth inhibition of *E. histolytica* trophozoites.

| Drug combination ratio | % growth inhibition | CI | DRI | Dose required (µM) |
|------------------------|---------------------|----|-----|-------------------|
| Lonafarnib: simvastatin |                     |    |     |                   |
| 1:1                    | 95                  | 1 ± 0.09 | 1.4 ± 0.37 | 15.9 ± 3.05 |
| 2:1                    | 95                  | 0.9 ± 0.12 | 1.2 ± 0.4 | 15.9 ± 3.05 |

CI, combination index; DRI, dose reduction index.

Mass-action law based computer software “CompuSyn” was used for automated data analysis. Experiments were carried out in triplicate. Table 5.

### TABLE 5 | Average cLogP values for FTIs according to group* in *E. histolytica*.

| Group | A | B | C | D |
|-------|---|---|---|---|
| No. of compounds | 17 | 25 | 40 | 40 |
| cLogP (mean) | 5.14 | 4.9 | 5.06 | 4.26 |
| SE | 0.19 | 0.18 | 0.15 | 0.20 |

*Groups A, B, and C each have cLogP values that are significantly higher than group D (P < 0.05, ANOVA).

### TABLE 6 | Average cLogP values for FTIs according to group* in *S. mansoni*.

| Group | A | B | C | D |
|-------|---|---|---|---|
| No. of compounds | 17 | 47 | 34 | 28 |
| cLogP (mean) | 5.32 | 5.28 | 4.89 | 3.66 |
| SE | 0.22 | 0.10 | 0.17 | 0.20 |

*Groups A, B, and C each have cLogP values that are significantly higher than group D (P < 0.001, ANOVA).
not mediated through inhibition of an FT enzyme, but could involve another cellular target that is sensitive to this chemotype. Alternatively, FT could be the target in *E. histolytica* as a result of differences in binding preferences compared to other FT enzymes (found in mammals and trypanosomes), but this will need further exploration.

Apart from targeting HMGR in the mevalonate pathway (which is absent in *E. histolytica*), statins exhibit other pleiotropic effects including the modulation of protein prenylation that then leads to the inhibition of the activity of cell signaling molecules including the Rab family of small GTP-binding proteins (Greenwood et al., 2006; Wang et al., 2008). The *E. histolytica* genome encodes heterotrimeric G protein subunits and a large number of small G proteins, which are involved in vesicular trafficking (Bosch and Siderovski, 2013). Accordingly, we measured the effect of statins against *E. histolytica*. Of the statins, mevastatin, atorvastatin, fluvastatin, pitavastatin, and simvastatin tested at 100 µM for 48 h, only simvastatin yielded moderate activity against *E. histolytica*. However, the combination of simvastatin and lonafarnib was slightly synergistic against *E. histolytica*, an intriguing finding given the apparent lack of a HMGR in the parasite.

Using microscopical observation and a constrained scoring system, lonafarnib, tipifarnib and the panel of 125 tipifarnib analogs were also screened in a time and/or concentration-dependent manner against *S. mansoni* somules and adults. Both lonafarnib and tipifarnib were among the most active Group A compounds, causing severe degenerative changes after 24 h in both developmental stages. FT activity has been documented in schistosomes and Ras farnesylation in both developmental stages. FT activity has been documented in compounds, causing severe degenerative changes after 24 h in both developmental stages. FT activity has been documented in schistosomes and Ras farnesylation in *S. mansoni* extracts has been inhibited by the FT inhibitor, FTI-277 (Osman et al., 1999). However, like the situation with *E. histolytica*, the tipifarnib analogs that were most active against the schistosome are weak inhibitors of trypanosomes and rat FTs (Buckner et al., 2000). This includes about half of the compounds shown in Table 7 (CHN-15, JK-02, JK-17, JK-19, JK-25, JK-35, PN-077, and PN-149; unpublished data). It is possible that the *S. mansoni* FT ortholog is sufficiently distinct from the FTIs of other species to limit the above SAR analysis. In this regard, it is worth noting that the three main schistosome species infecting humans all carry a FT gene, but the percentage identities are modest with approximately 36% identity across 79% of the human FT sequence (PF49354.1).

It is possible that the higher cLogP values (associated with greater lipophilicity) better facilitated permeability of *E. histolytica* and *S. mansoni*. Previously, for the latter parasite, the bioactivity of six statin analogs was positively associated with lipophilicity (Rojo-Arreola et al., 2014).

Although FTIs showed moderate activity against *E. histolytica* with EC₅₀ values ranging from 14.2 to 27.6 µM, we see potential in the use of FTIs in combination with metronidazole. The combination of lonafarnib and metronidazole at 1:1, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, and 1:256 elicited synergistic activity with CI values ranging from 0.5 to 0.8. Thus, the dose of either one or both compounds necessary for complete growth inhibition of the parasite can be reduced.

To conclude, we report the potent anti-amebic and anti-schistosomal activities of the clinically developed FTIs, lonafarnib and tipifarnib. Screening of a previously developed tipifarnib analog library comprising 125 compounds identified subsets of potent compounds with little overlap between *E. histolytica* and *S. mansoni*. Also, scrutiny of the SAR data available for this set of compounds against trypanosomatid parasites, suggests that neither the *E. histolytica* nor the *S. mansoni* FT seems to be the target responsible for the bioactivities recorded. Nonetheless, the potent bioactivities measured encourage further study. Finally, the synergistic activity of the combination of lonafarnib and metronidazole against *E. histolytica* provides an opportunity to investigate a combination therapy for amebiasis.

### AUTHOR CONTRIBUTIONS

AP performed experiments, analyzed the data, and prepared the original draft. TN performed experiments and analyzed

| Table 7 | First pass screening of FTIs at 10µM against *S. mansoni* somules and adults. |
|----------------|-------------------------------------------------|
| **Compound** | **Somule severity score at 48 h** | **Adult severity score at 48 h** |
| Lonafarnib* | 4 | 4 |
| Tipifarnib* | 4 | 4 |
| CHN-13* | 4 | 4 |
| CHN-15 | 4 | 4 |
| HB-19 | 4 | 4 |
| HB-20 | 4 | 4 |
| HB-23 | 4 | 4 |
| HB-26 | 4 | 4 |
| JK-02* | 4 | 1 |
| JK-17* | 4 | 2 |
| JK-19* | 4 | 4 |
| JK-24 | 4 | 4 |
| JK-25 | 4 | 4 |
| JK-31 | 4 | 4 |
| JK-35 | 4 | 4 |
| PN-149 | 4 | 3 |
| PN-077 | 4 | 4 |

Screens were performed twice each in duplicate and representative data are shown. Compounds with asterisks were also those most potent against *E. histolytica* in first pass screens (Table 1).
AD was supported by the National Institutes of Health, Grant no. 1KL2TR001444 and UCSD Academic Senate Grant. TN was supported by 1TL1TR001443. Schistosome screens were made possible in part by an NIH-NIAID award R21AI126296 to CC. S. mansoni-infected and uninfected B. glabrata snails were supplied in part by the NIAID Schistosomiasis Resource Center (Biomedical Research Institute, Rockville, MD) through the NIH-NIAID Contract HHSN2722010000051. FB and MG were supported by NIH grants: R01AI070218 and R01AI106850. ChemAxon’s JChem for Office (Excel; Version 15.1.990.1773) was used to display the structures shown in Supplementary Table 2 (http://www.chemaxon.com).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2019.00180/full#supplementary-material

Supplementary Table 1 | Chemical structures and properties of analogs of tipifarnib and their activity against E. histolytica trophozoites. NA means compound was not available for testing.

Supplementary Table 2 | Chemical structures of tipifarnib analogs and their activity against S. mansoni somules and adults.

Supplementary Video 1 | DMSO control adult S. mansoni incubated for 24 h. Three male parasites are visible. Note the flexibility of the parasites and their ability to grasp the well bottom with their oral and ventral suckers.

Supplementary Video 2 | Adult S. mansoni incubated for 24 h in the presence of 10 µM tipifarnib. Five male parasites are visible in the movie. Relative to the DMSO control parasites (Supplementary Video 1), note the uncoordinated movement, more constrained flexibility, darkened appearance and the inability of the parasites to adhere to the well bottom with their oral and ventral suckers.

REFERENCES

Abdulla, M. H., Ruelas, D. S., Wolff, B., Snezdecor, J., Lim, K. C., Xu, F., et al. (2009). Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Negl. Trop. Dis. 3:e478. doi: 10.1371/journal.pntd.0000478

Andrews, P., Thomas, H., Pohlke, R., and Seubert, J. (1983). Praziquantel. Med. Res. Rev. 3, 147–200.

Asarown, D., Rojo-Arreola, L., Suzuki, B. M., Caffrey, C. R., and Singh, R. (2015). The QDREC web server: determining dose-response characteristics of complex macroparasites in phenotypic drug screens. Bioinformatics 31, 1515–1518. doi: 10.1093/bioinformatics/btu831

Bagchi, S., Rathee, P., Jayaprakash, V., and Banerjee, S. (2018). Farnesyl transferase inhibitors as potential anticancer agents. Mini Rev. Med. Chem. 18, 1611–1623. doi: 10.2174/13895571866618080110342

Basch, P. F. (1981). Cultivation of Schistosoma mansoni in vitro. I. Establishment of cultures from cercariae and development until pairing. J. Parasitol. 67, 179–185.

Bosch, D. E., and Siderovski, D. P. (2013). G protein signaling in the parasite Entamoeba histolytica. Exp. Mol. Med. 45:e15. doi: 10.1038/emm.2013.30

Buckner, F. S., Eastman, R. T., Nepomuceno-Silva, J. L., Speelman, E. C., Myler, P. J., Van Voorhis, W. C., et al. (2002). Cloning, heterologous expression, and substrate specificities of protein farnesyltransferases from Trypanosoma cruzi and Leishmania major. Mol. Biochem. Parasitol. 122, 181–188. doi: 10.1016/S0166-6851(02)00099-3

Buckner, F. S., Eastman, R. T., Yokoyama, K., Gelb, M. H., and Van Voorhis, W. C. (2005). Protein farnesyl transferase inhibitors for the treatment of malaria and African trypanosomiasis. Curr. Opin. Investig. Drugs 6, 791–797.

Buckner, F. S., Yokoyama, K., Nguyen, L., Rewal, A., Ejdunm-Bromage, H., Tempst, P., et al. (2000). Cloning, heterologous expression, and distinct substrate specificity of protein farnesyltransferase from Trypanosoma brucei. J. Biol. Chem. 275, 21870–21876. doi: 10.1074/jbc.M000975200

Caffrey, C. R. (2007). Chemotherapy of schistosomiasis: present and future. Curr. Opin. Chem. Biol. 11, 433–439. doi: 10.1016/j.cpb.2007.05.031

Caffrey, C. R. (2015). Schistosomiasis and its treatment. Fut. Med. Chem. 7, 675–676. doi: 10.4155/fmc.15.27

Carrodo, D., Ohkanda, J., Kendrick, H., Yokoyama, K., Blaskovich, M. A., Bucher, C. J., et al. (2004). In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. Bioorg. Med. Chem. 12, 6517–6526. doi: 10.1016/j.bmc.2004.09.020

Chakrabarti, D., Da Silva, T., Barger, J., Paquette, S., Patel, H., Patterson, S., et al. (2002). Protein farnesyltransferase and protein prenylation in Plasmodium falciparum. J. Biol. Chem. 277, 42066–42073. doi: 10.1074/jbc.M202860200

Chou, T. C. (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621–681. doi: 10.1124/pr.58.3.10

Chou, T. C., and Talalay, P. (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27–55.

Debnath, A., Parsonage, D., Andrade, R. M. H., Ce, C., Cobo, E. R., Hirata, K., et al. (2012). A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nat. Med. 18, 956–960. doi: 10.1038/nm.2758

Debnath, A., Shahinas, D., Bryant, C., Hirata, K., Miyamoto, Y., Hwang, G., et al. (2014). Hsp90 inhibitors as new leads to target parasitic diarrheal diseases. Antimicrob. Agents Chemother. 58, 4138–4144. doi: 10.1128/AAC.02576-14

Diamond, L. S., Harlow, D. R., and Cunnick, C. C. (1978). A new medium for the axenic cultivation of Entamoeba histolytica and other Entamoeba. Trans. R. Soc. Trop. Med. Hyg. 72, 431–432.

Edwards, D. I. (1993). Nitroimidazole drugs–action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother 31, 9–20.

Edwards, P. A., and Ericsson, J. (1999). Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annu. Rev. Biochem. 68, 137–185. doi: 10.1146/annurev.biochem.68.1.1157

Emmanuel, M., Nakanoy, Y. S., Nosuki, T., and Datta, S. (2015). Small GTPase Rab21 mediates fibroectin induced actin reorganization in Entamoeba histolytica: implications in pathogen invasion. PLoS Pathog. 11:e1004666. doi: 10.1371/journal.ppat.1004666

Esteva, M. I., Kettler, K., Maidana, C., Fichera, L., Ruiz, A. M., Bontempi, E. J., et al. (2005). Benzophenone-based farnesyltransferase inhibitors with high activity against Trypanosoma cruzi. J. Med. Chem. 48, 7186–7191. doi: 10.1021/jm050456x

Gazzero, P., Proto, M. C., Gangemi, G., Malfitano, A. M., Ciaglia, E., Pisanti, S., et al. (2012). Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol. Rev. 64, 102–146. doi: 10.1124/pr.111.004994

Glarer, J., Schurigt, U., Suzuki, B. M., Caffrey, C. R., and Holzgrabe, U. (2015). Anti-schistosomal activity of cinnamic acid esters: eugenyl and thymyl cinnamate induce cytoplasmic vacuoles and death in schistosomula of Schistosoma mansoni. Molecules 20, 10873–10883. doi: 10.3390/molecules200610873

Goldstein, J. L., and Brown, M. S. (1990). Regulation of the mevalonate pathway. Nature 343, 425–430. doi: 10.1038/343425a0
Farnesyltransferase Inhibitors Against Entamoeba, Schistosoma

Gordon, L. B., Kleinman, M. E., Massaro, J., D’Agostino, R. B. Sr., Shappell, H., Gerhard-Herman, M., et al. (2016). Clinical trial of the protein farnesyltransferase modifiers lonafarnib, pravastatin, and zoladex in children with Duchenne-gilford progeria syndrome. Circulation 134, 114–125. doi: 10.1161/CIRCULATIONAHA.116.022188

Gordon, L. B., Shappell, H., Massaro, J., D’Agostino, R. B. Sr., Brazier, J., Campbell, S. E., et al. (2018). Association of lonafarnib treatment vs no treatment with mortality rate in patients with Hutchinson-Gilford Progeria syndrome. JAMA 319, 1687–1695. doi: 10.1001/jama.2018.3264

Greenwood, J., Steinman, L., and Zamvil, S. S. (2006). Statin therapy and quantitative structural analysis. Curr. Med. Chem. 20, 4888–4923. doi: 10.2174/0929867311320660262

Muller, M. (1983). Mode of action of metronidazole on anaerobic bacteria and protozoa. Surgery 93(1 Pt 2), 163–171.

Osman, A., Niles, E. G., and LoVerde, P. T. (1999). Characterization of the Ras homologue of Schistosoma mansoni. Mol. Biochem. Parasitol. 100, 27–41.

Petri, W. A. Jr. (2002). Pathogenesis of amebiasis. Curr. Opin. Microbiol. 5, 443–447. doi: 10.1016/S1369-5274(02)00335-1

Petri, W. A. Jr., and Singh, U. (1999). Diagnosis and management of amebiasis. Clin. Infect. Dis. 29, 1117–1125. doi: 10.1086/313493

Rojo-Arreola, L., Long, T., Asarnow, D., Suzuki, B. M., Singh, R., and Caffrey, C. R. (2014). Chemical and genetic validation of the statin drug target to treat the helmint disease, schistosomiasis. PLoS ONE 9:e87594. doi: 10.1371/journal.pone.0087594

Samarawickrema, N. A., Brown, D. M., Upcroft, J. A., Thammapalard, N., and Upcroft, P. (1997). Infection of superoxide dismutase and pyruvate:ferredoxin oxidoreductase in mechanisms of metronidazole resistance in Entamoeba histolytica. J. Antimicrob. Chemother. 40, 833–840.

Stanley, S. L. Jr. (2003). Amebiasis. Lancet 361, 1025–1034. doi: 10.1016/S0140-6736(03)12830-9

Stauffer, W., and Ravdin, J. I. (2003). Entamoeba histolytica: an update. Curr. Opin. Infect. Dis. 16, 479–485. doi: 10.1097/01.qco.0000092821.42392.ca

Sztastnik, S., Dvorák, J., Horn, M., Braschi, S., and Sojka, D., Ruela, D.S., et al. (2010). RNA interference in Schistosoma mansoni schistosomiasis: selectivity, sensitivity and operation for larger-scale screening. PLoS Negl. Trop. Dis. 4:e850. doi: 10.1371/journal.pntd.0000850

Utzinger, J., N’Goran, E. K., Caffrey, C. R., and Keiser, J. (2011). From innovation to application: social-ecological context, diagnostics, drugs and integrated control of schistosomiasis. Acta Trop. 120(Suppl. 1):S121–37. doi: 10.1016/j.actatropica.2010.08.020

Wang, C. Y., Liu, P. Y., and Liao, J. K. (2008). Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol. Med. 14, 37–44. doi: 10.1016/j.molmed.2007.11.004

Wassmann, C., Hellberg, A., Tannich, E., and Bruchhaus, I. (1999). Metronidazole resistance in the protozoan parasite Entamoeba histolytica is associated with increased expression of iron-containing superoxide dismutase and peroxiredoxin and decreased expression of ferredoxin 1 and flavin reductase. J. Biol. Chem. 274, 26051–26056.

Watanahe, K., and Petri, W. A. Jr. (2015). Molecular biology research to benefit patients with Entamoeba histolytica infection. Mol. Microbiol. 98, 208–217. doi: 10.1111/mmi.13131

Weeks, J. C., Roberts, W. M., Leasure, C., Suzuki, B. M., Robinson, K. J., Currey, H., et al. (2018). Sertraline, Paroxetine, and Chlorthromazine Are Rapidly Acting Anthelmintic Drugs Capable of Clinical Repurposing. Sci. Rep. 8:975. doi: 10.1038/s41598-017-18457-w

Zhang, F. L., and Casey, P. J. (1996). Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65, 241–269. doi: 10.1146/annurev.bi.65.070196.001325

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.